[Skip to Content]
[Skip to Content Landing]

September 2019 - April 2016

Decade

Year

Issue

August 2019, Vol 4, No. 8, Pages 719-833

In This Issue of JAMA Cardiology

Highlights

Abstract Full Text
free access
JAMA Cardiol. 2019;4(8):719. doi:10.1001/jamacardio.2018.3210
Original Investigation

Association of Coronary Anatomical Complexity With Clinical Outcomes After Percutaneous or Surgical Revascularization in the Veterans Affairs Clinical Assessment Reporting and Tracking Program

Abstract Full Text
has audio
JAMA Cardiol. 2019;4(8):727-735. doi:10.1001/jamacardio.2019.1923

This cross-sectional multiple-center study adapts an anatomical scoring system for use with registry data, allowing facile and automatic calculation of scores and association with clinical outcomes among patients undergoing percutaneous or surgical revascularization.

Temporal Changes in Coronary Hyperemic and Resting Hemodynamic Indices in Nonculprit Vessels of Patients With ST-Segment Elevation Myocardial Infarction

Abstract Full Text
JAMA Cardiol. 2019;4(8):736-744. doi:10.1001/jamacardio.2019.2138

This cohort study assesses changes in nonhyperemic and hyperemic hemodynamic stenosis and resistance indices in nonculprit vessels in patients with ST-segment elevation myocardial infarction (STEMI).

Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials

Abstract Full Text
has active quiz
JAMA Cardiol. 2019;4(8):747-755. doi:10.1001/jamacardio.2019.1880

This network meta-analysis of randomized controlled trials examines the safety and efficacy of different antithrombotic regimens.

Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation

Abstract Full Text
open access
JAMA Cardiol. 2019;4(8):756-764. doi:10.1001/jamacardio.2019.1960

This study assesses whether a history of warfarin therapy in patients with atrial fibrillation is independently associated with subsequent bleeding or thrombotic events.

Vitamin D Supplementation and Cardiovascular Disease Risks in More Than 83 000 Individuals in 21 Randomized Clinical Trials: A Meta-analysis

Abstract Full Text
JAMA Cardiol. 2019;4(8):765-775. doi:10.1001/jamacardio.2019.1870

This meta-analysis of 21 randomized clinical trials examines the role of vitamin D supplementation in reducing cardiovascular events and all-cause mortality.

Effect of Aerobic and Resistance Exercise on Cardiac Adipose Tissues: Secondary Analyses From a Randomized Clinical Trial

Abstract Full Text
JAMA Cardiol. 2019;4(8):778-787. doi:10.1001/jamacardio.2019.2074

This secondary analysis of a randomized clinical trial assesses whether a 12-week endurance or resistance training intervention can regulate epicardial and pericardial adipose tissue mass.

Systolic Blood Pressure and Risk of Valvular Heart Disease: A Mendelian Randomization Study

Abstract Full Text
JAMA Cardiol. 2019;4(8):788-795. doi:10.1001/jamacardio.2019.2202

This population-based study uses mendelian randomization to evaluate whether there is an association between elevated systolic blood pressure and valvular heart disease.

Association of Silent Myocardial Infarction and Sudden Cardiac Death

Abstract Full Text
JAMA Cardiol. 2019;4(8):796-802. doi:10.1001/jamacardio.2019.2210

This case-control study uses existing medical records and autopsy data to assess the prevalence of silent myocardial infarction and electrocardiographic abnormalities in individuals who experienced sudden cardiac death without a prior diagnosis of coronary artery disease.

Brief Report

Use of Cardiac Resynchronization Therapy Defibrillator in US Hospitals

Abstract Full Text
JAMA Cardiol. 2019;4(8):804-809. doi:10.1001/jamacardio.2019.1755

This population-based study describes use of the cardiac resynchronization therapy defibrillator when the 2012 American College of Cardiology/American Heart Association/Heart Rhythm Society guidelines for device-based therapy of cardiac rhythm abnormalities were revised.

Comparison of Outcomes After Transcatheter vs Surgical Aortic Valve Replacement Among Patients at Intermediate Operative Risk With a History of Coronary Artery Bypass Graft Surgery: A Post Hoc Analysis of the SURTAVI Randomized Clinical Trial

Abstract Full Text
JAMA Cardiol. 2019;4(8):810-814. doi:10.1001/jamacardio.2019.1856

This post hoc analysis of a randomized clinical trial compares outcomes after transcatheter vs surgical aortic valve replacement in patients at intermediate operative risk with a history of coronary artery bypass graft surgery.

Research Letter

Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D

Abstract Full Text
JAMA Cardiol. 2019;4(8):828-830. doi:10.1001/jamacardio.2019.2223

This study examines the insurance coverage and out-of-pocket costs to Medicare beneficiaries for the angiotensin receptor–neprilysin inhibitor sacubitril/valsartan.

Viewpoint

Nonarrhythmic Sudden Cardiac Death in Chronic Heart Failure—A Preventable Event?

Abstract Full Text
JAMA Cardiol. 2019;4(8):721-722. doi:10.1001/jamacardio.2019.2228

This Viewpoint describes the means by which sudden cardiac death arises in patients who have implantable cardioverter-defibrillators.

Fear-Based Medical Misinformation and Disease Prevention: From Vaccines to Statins

Abstract Full Text
JAMA Cardiol. 2019;4(8):723-724. doi:10.1001/jamacardio.2019.1972

This Viewpoint discusses how antivaccination sentiment has extended to use of statins and outlines ways physicians can combat antistatin misinformation.

From the Heart

Electrified

Abstract Full Text
JAMA Cardiol. 2019;4(8):725-726. doi:10.1001/jamacardio.2019.1661

This essay describes 2 decades of life with an implantable pacemaker-defibrillator, including the author’s loss of all underlying heart rhythm.

Invited Commentary

Assessing Nonculprit Coronary Disease in ST-Segment Elevation Myocardial Infarction With Physiological Testing

Abstract Full Text
JAMA Cardiol. 2019;4(8):745-746. doi:10.1001/jamacardio.2019.2217

The Demise of Vitamin D for Cardiovascular Prevention

Abstract Full Text
JAMA Cardiol. 2019;4(8):776-777. doi:10.1001/jamacardio.2019.1906

Frequency of Left Ventricular Scars at Autopsy in Persons Dying Suddenly of Coronary Artery Disease With or Without Earlier Myocardial Infarction

Abstract Full Text
JAMA Cardiol. 2019;4(8):802-803. doi:10.1001/jamacardio.2019.2238
Review

Palliative Inotrope Therapy: A Narrative Review

Abstract Full Text
has active quiz
JAMA Cardiol. 2019;4(8):815-822. doi:10.1001/jamacardio.2019.2081

This narrative review provides guidance to clinicians on initiation, selection, maintenance, and weaning or withdrawal of chronic inotropes and the management of concurrent therapies in the modern heart failure landscape.

JAMA Cardiology Clinical Challenge

A 44-Year-Old Woman With Dilated Cardiomyopathy

Abstract Full Text
has active quiz
JAMA Cardiol. 2019;4(8):825-826. doi:10.1001/jamacardio.2019.1146

A 44-year-old woman presents with dilated cardiomyopathy after ventricular fibrillation arrest and receives several shocks from an impanted subcutaneous cardioverter defibrillator. What would you do next?

JAMA Cardiology Clinical Guidelines Synopsis

Evaluation and Treatment of Patients With Bradycardia and Cardiac Conduction Delay: Recommendations for Permanent Pacing

Abstract Full Text
JAMA Cardiol. 2019;4(8):823-824. doi:10.1001/jamacardio.2019.1231

This Clinical Guidelines Synopsis summarizes the 2018 American College of Cardiology/American Heart Association/Heart Rhythm Society Guideline on Bradycardia and Conduction Delay and reviews recommendations for permanent pacing.

Comment & Response

The Incompleteness of the Social Security Death Master File

Abstract Full Text
JAMA Cardiol. 2019;4(8):831. doi:10.1001/jamacardio.2019.1877

Hypertrophic Cardiomyopathy—Need for Gene-Specific Treatment?

Abstract Full Text
JAMA Cardiol. 2019;4(8):831-832. doi:10.1001/jamacardio.2019.1752

Hypertrophic Cardiomyopathy—Need for Gene-Specific Treatment?—Reply

Abstract Full Text
JAMA Cardiol. 2019;4(8):831-832. doi:10.1001/jamacardio.2019.1766

Studies Evaluating Statin Adherence and Outcome Should Adjust for Smoking Persistence and Antiplatelet Treatment Discontinuation

Abstract Full Text
JAMA Cardiol. 2019;4(8):832-833. doi:10.1001/jamacardio.2019.1966

Studies Evaluating Statin Adherence and Outcome Should Adjust for Smoking Persistence and Antiplatelet Treatment Discontinuation—Reply

Abstract Full Text
JAMA Cardiol. 2019;4(8):832-833. doi:10.1001/jamacardio.2019.1969
Editor's Note

Impediments to Implementing Guideline-Directed Medical Therapies

Abstract Full Text
JAMA Cardiol. 2019;4(8):830-831. doi:10.1001/jamacardio.2019.2276
Correction

Error in Corresponding Author’s Email Address

Abstract Full Text
free access
JAMA Cardiol. 2019;4(8):833. doi:10.1001/jamacardio.2019.2930
JAMA Cardiology Masthead

JAMA Cardiology

Abstract Full Text
free access
JAMA Cardiol. 2019;4(8):720. doi:10.1001/jamacardio.2018.3211
×